← Back to Search

Cannabinoid

THC for Cannabis Use

Phase < 1
Recruiting
Led By Natania A Crane, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must not be taking psychoactive medications that would interfere with dronabinol and/or interpretation of fMRI data, including but not limited to the following classes of psychotropics: antidepressants, anxiolytics, sedative hypnotics, stimulants, antipsychotics, mood stabilizer
negative urine drug screen (UDS) for all substances except THC (THC allowed)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first and second laboratory visit, at baseline (time 0) and at peak drug response (90-120 minutes) after drug administration. outcome measure is change in peak score during placebo (peak minus baseline) compared to change in peak score during thc
Awards & highlights

Study Summary

This trial will study how THC affects the brain's reward system.

Who is the study for?
This trial is for healthy, English-speaking adults with a BMI of 19-26 who've used cannabis over 10 times but not daily. They must have no severe drug use disorders or need for psychoactive meds, and be free from medical conditions that affect MRI results or are worsened by THC.Check my eligibility
What is being tested?
The study examines how THC affects mood and brain responses in non-daily cannabis users compared to a placebo. Participants will undergo fMRI scans to track brain activity changes related to the rewarding effects of THC.See study design
What are the potential side effects?
THC can cause altered mental states, anxiety, changes in mood, sensory perception alterations, increased heart rate, dry mouth, red eyes, coordination issues and memory impairment.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not taking any medications that affect mood or the way my brain works.
Select...
My drug test was negative, except for THC.
Select...
My drug test was negative, except for THC.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first and second laboratory visit, at baseline (time 0) and at peak drug response (90-120 minutes) after drug administration. outcome measure is change in peak score during placebo (peak minus baseline) compared to change in peak score during thc
This trial's timeline: 3 weeks for screening, Varies for treatment, and first and second laboratory visit, at baseline (time 0) and at peak drug response (90-120 minutes) after drug administration. outcome measure is change in peak score during placebo (peak minus baseline) compared to change in peak score during thc for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Neural reward response- Reward Positivity (RewP) event-related potential
Neural reward response- blood-oxygen-level-dependent (BOLD) response
Subjective drug response- Addiction Research Center Inventory (ARCI)- Morphine Benzedrine Group (MBG) subscale

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: THCExperimental Treatment1 Intervention
Participants will receive THC (7.5 mg) at their first or second laboratory visit.
Group II: Placebo oral capsulePlacebo Group1 Intervention
Participants will receive a placebo at their first or second laboratory visit.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dronabinol
FDA approved

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
607 Previous Clinical Trials
1,559,275 Total Patients Enrolled
1 Trials studying Cannabis Use
200 Patients Enrolled for Cannabis Use
National Institute on Drug Abuse (NIDA)NIH
2,467 Previous Clinical Trials
2,619,043 Total Patients Enrolled
28 Trials studying Cannabis Use
6,077 Patients Enrolled for Cannabis Use
Natania A Crane, PhDPrincipal Investigator - University of Illinois at Chicago
University of Illinois at Chicago

Media Library

THC (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04512365 — Phase < 1
Cannabis Use Research Study Groups: THC, Placebo oral capsule
Cannabis Use Clinical Trial 2023: THC Highlights & Side Effects. Trial Name: NCT04512365 — Phase < 1
THC (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04512365 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who can participate in this experiment?

"This unique trial is in search of 80 individuals aged 18 to 25 that are active users of cannabis."

Answered by AI

How is tetrahydrocannabinol ordinarily utilized for therapeutic purposes?

"When inadequate response to conventional therapy, plasmapheresis, and pharmacotherapy is observed THC can be administered as an alternative treatment."

Answered by AI

What other investigations have been conducted concerning THC?

"Currently, 45 investigations into the therapeutic potential of THC are in progress. Of these studies, 9 have reached Phase 3. Additionally, while Belmont: Massachusetts is the main hub for this research; 307 other clinical trial sites across America offer trials concerning THC's benefits and drawbacks."

Answered by AI

Is admission to this trial limited to subjects over 30?

"In order to be considered for this trial, participants must fall within the 18-25 age bracket. There are 67 trials currently running that cater to those under 18 and 445 studies specifically targeting seniors above 65 years of age."

Answered by AI

Is enrollment currently open for this investigative study?

"Affirmative, the clinical trial is still looking for volunteers. It was initially posted on March 16th 2021 and has most recently been updated on August 12th 2022; 80 participants are needed from a single site."

Answered by AI

How many people are partaking in this experiment at its peak?

"Affirmative. Clinicaltrials.gov contains the data to suggest that this medical trial, which first appeared on March 16th 2021, is still actively seeking volunteers. The research team requires 80 participants across a single site for their study."

Answered by AI

Is this a pioneering research endeavor?

"Currently, 45 active trials for THC are hosted in 190 cities and 30 nations. The initial trial took place 13 years ago under Baxter Healthcare Corporation's auspices with 4640 participants and was able to reach Phase 4 drug approval status. In the thirteen subsequent years, 349 studies have been completed."

Answered by AI

Who else is applying?

What state do they live in?
Florida
Idaho
How old are they?
18 - 65
What site did they apply to?
University of Illinois at Chicago
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Reward and Drug Effects on Mood and Brain Response
Natania A Crane 2021. "Reward and Drug Effects on Mood and Brain Response". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04512365.
All > Cannabis
~22 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top